Clinical trials: Monoclonal Antibody
Arthritis, Psoriatic
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug Therapy
- Trial name
- NCT00646178
- Testing
- adalimumab
- Volunteers
- 102 people
- Sponsor
- Abbott
Multiple Myeloma
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade).
- Trial name
- NCT00401843
- Testing
- Siltuximab, Bortezomib, Dexamethasone
- Where
- 80 sites in United States, Belgium and 16 more
- Volunteers
- 307 people
- Sponsor
- Janssen Research & Development, LLC
Malaria,Falciparum
Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali
Mali faces a significant challenge with malaria, particularly among its younger population. While existing measures like seasonal chemoprevention and vaccination have shown efficacy, further innovations are necessary to combat…
- Trial name
- NCT06413108
- Testing
- TB31F, Normal saline
- Where
- Mali
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Solid Tumors
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.
- Trial name
- NCT00555724
- Testing
- BIIB022
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Biogen
Breast Cancer
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
The purpose of this study is to evaluate the safety and effectiveness of combined treatment with trastuzumab (Herceptin) and bevacizumab (anti-VEGF antibody) in patients with HER2-positive metastatic breast cancer.
- Trial name
- NCT00095706
- Testing
- Bevacizumab (drug), Herceptin (drug)
- Where
- 18 sites in United States
- Volunteers
- 50 people
- Sponsor
- Translational Oncology Research International
Healthy
A Preliminary Study to Evaluate PF-07264660 in Healthy Participants
The purpose of this clinical trial is to learn about the safety and effects of study medicine PF-07264660 compared to a placebo. This is the first study of PF-07264660 in humans.
- Trial name
- NCT05496738
- Testing
- PF-07264660 intravenous single ascending dose, PF-07264660 subcutaneous multiple ascending dose
- Where
- 6 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Pfizer
Congenital Heart Disease
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
- Trial name
- NCT00538785
- Testing
- Motavizumab, Palivizumab
- Where
- 152 sites in United States, Austria and 15 more
- Volunteers
- 1,236 people
- Sponsor
- MedImmune LLC
Colorectal Cancer
Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002664
- Testing
- edrecolomab, sargramostim
- Where
- United States
- Sponsor
- James Ahlgren
Lung Cancer
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084799
- Testing
- monoclonal antibody hu3S193
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ludwig Institute for Cancer Research
Pharmacokinetics
Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects
Research Topics A randomized, open-label, parallel-group, phase I clinical trial comparing the pharmacokinetics of MG-K10 humanized monoclonal antibody in healthy adults
- Trial name
- NCT06277284
- Testing
- MG-K10 humanized monoclonal antibody injection (prefilled syringe), MG-K10 humanized monoclonal antibody injection（Penicillin bottle）
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Neoplasms
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
A dose escalation study to establish the safety profile and characterize the pharmacokinetic profile of IMC-CS4 in the treatment of subjects with advanced solid tumors refractory to standard therapy or for which no standard…
- Trial name
- NCT01346358
- Testing
- IMC-CS4
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05536726
- Testing
- 608 Q2W, 608 Q4W
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma Attack, Asthma
Benralizumab Initiated During Severe Asthma Attack
Approximately 300 million people have asthma worldwide and 400,000 people died from asthma globally in 2015 (GINA Asthma). Singapore's asthma mortality and hospitalisation rates are several times higher than OECD countries.
- Trial name
- NCT04617171
- Testing
- Benralizumab 30 MG/ML [Fasenra]
- Where
- Singapore
- Volunteers
- 128 people
- Sponsor
- Singapore General Hospital
Systemic Lupus Erythematosus
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to…
- Trial name
- NCT04179032
- Testing
- Belimumab
- Where
- 11 sites in United States, Argentina and 5 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.
- Trial name
- NCT00528333
- Testing
- Lintuzumab (SGN-33), Low dose cytarabine
- Where
- 20 sites in United States
- Volunteers
- 211 people
- Sponsor
- Seagen Inc.
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
Patients With Cancer
Radioimmunotherapy With 131I-L19SIP in Patients With Cancer
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-L19SIP as an anti-cancer therapeutic agent, following the promising results of a Phase I study.
- Trial name
- NCT01242943
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT)
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 34 people
- Sponsor
- Philogen S.p.A.
Hematologic Malignancies
Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation
This study will determine the Maximal Tolerated Dose if any and the recommended dose for phase 2 of monalizumab, a monoclonal antibody directed against the CD94/NKG2A receptor, after allogenic stem cell transplantation.
- Trial name
- PIRAT (NCT02921685)
- Testing
- Monalizumab
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut Paoli-Calmettes
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
This phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
- Trial name
- NCT05139004
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Dermatitis, Atopic
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy of 611 in Chinese Adolescents with moderate to severe atopic dermatitis.
- Trial name
- NCT07042126
- Testing
- 611
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.